Yihong Qiu

This inventor holds 17 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Formulations. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Neurocrine Biosciences, Inc.. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yihong Qiu. Retrieved from https://idiyas.com/inventor/yihong-qiu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 13)

% Patents Active = 82.4

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 224(Granted Patents)

Location History:

Gumee, IL (US) (2003 - 2004)
Vernon Hills, IL (US) (2011 - 2013)
Gurnee, IL (US) (2000 - 2015)
North Chicago, IL (US) (2024)

Company Filing History:

13 out of 4,190

Abbott Laboratories Corporation

Neurocrine Biosciences, Inc.

where one patent can have more than one assignee

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

Uridine Triacetate

Solid Pharmaceutical Formulations

Endometriosis Treatment

Lipid-Regulating Drugs

Sustained Release

Controlled Release

Opioid Analgesics

Nonopioid Analgesics

Crystallization Inhibitors

Solid Dispersion

Enhanced Dissolution

pH Independent Formulations

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758570 - Uridine triacetate amorphous formulation (2026-10-13),

2. 12083227 - Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis (2024-09-10),

3. 9107830 - Inhibitors of crystallization in a solid dispersion (2015-08-18),

4. 8541026 - Sustained release formulations of opioid and nonopioid analgesics (2013-09-24),

5. 8062664 - Process for preparing formulations of lipid-regulating drugs (2011-11-22),

6. 7364752 - Solid dispersion pharamaceutical formulations (2008-04-29),

7. 6720004 - Controlled release formulation of divalproex sodium (2004-04-13),

8. 6713086 - Controlled release formulation of divalproex sodium (2004-03-30),

9. 6528091 - Controlled release formulation of divalproex sodium (2003-03-04),

10. 6528090 - Controlled release formulation of divalproex sodium (2003-03-04),

11. 6511678 - Controlled release formulation of divalproex sodium (2003-01-28),

12. 6419953 - Controlled release formulation of divalproex sodium (2002-07-16),

13. 6383517 - Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption (2002-05-07),

14. 6368622 - Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption (2002-04-09),

15. 6180138 - Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption (2001-01-30),

Title: Yihong Qiu: Innovator in Pharmaceutical Formulations

Introduction

Yihong Qiu is a prominent inventor based in Gurnee, IL (US), known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has made remarkable advancements in the treatment of various medical conditions.

Latest Patents

Among his latest patents is a formulation aimed at treating endometriosis, uterine fibroids, polycystic ovary syndrome, or adenomyosis. This patent focuses on pharmaceutical compositions that include a gonadotropin-releasing hormone (GnRH) antagonist, along with methods for preparing and utilizing these compositions. Another notable patent involves inhibitors of crystallization in a solid dispersion. This pharmaceutical composition consists of a solid dispersion of a pharmaceutical compound in a water-soluble carrier, such as polyethylene glycol (PEG), combined with a crystallization inhibitor like polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion can be encapsulated in hard gelatin capsules, compressed into tablets, or granulated with a pharmaceutically acceptable granulating agent.

Career Highlights

Yihong Qiu has worked with leading companies in the pharmaceutical industry, including Abbott Laboratories Corporation and AbbVie Inc. His work has significantly impacted the development of innovative treatments in the medical field.

Collaborations

Throughout his career, Yihong has collaborated with notable professionals, including Kevin R Engh and J Daniel Bollinger. These collaborations have further enhanced his contributions to pharmaceutical innovations.

Conclusion

Yihong Qiu's work in pharmaceutical formulations showcases his dedication to improving healthcare through innovation. His patents reflect a commitment to addressing complex medical issues, making him a valuable figure in the field of pharmaceuticals.

Profile summary based on public USPTO records.